Case Report: Immune Checkpoint Blockade Plus Interferon-Γ Add-On Antifungal Therapy in the Treatment of Refractory Covid-Associated Pulmonary Aspergillosis and Cerebral Mucormycosis

Alexandra Serris; Amani Ouedrani; Fabrice Uhel; Marianne Gazzano; Vincent Bedarida; Claire Rouzaud; Marie-Elisabeth Bougnoux; Jean-Herlé Raphalen; Sylvain Poirée; Olivier Lambotte; Guillaume Martin-Blondel; Fanny Lanternier

doi:10.3389/fimmu.2022.900522

Case Report: Immune Checkpoint Blockade Plus Interferon-Γ Add-On Antifungal Therapy in the Treatment of Refractory Covid-Associated Pulmonary Aspergillosis and Cerebral Mucormycosis

Alexandra Serris
, Amani Ouedrani
, Fabrice Uhel
, Marianne Gazzano
, Vincent Bedarida
, Claire Rouzaud
, Marie-Elisabeth Bougnoux
, Jean-Herlé Raphalen
, Sylvain Poirée
, Olivier Lambotte
, Guillaume Martin-Blondel
, Fanny Lanternier^*

^*Corresponding author for this work

Affiliatie UvA

Université Paris Cité
Université Paris Diderot
Assistance publique – Hôpitaux de Paris
Sorbonne Université
Université Paris 7
Université Paris-Saclay
CHU de Toulouse
CNRS

Research output: Contribution to journal › Article › Academic › peer-review

25 Downloads (Pure)

Abstract

Invasive fungal diseases (IFD) still cause substantial morbidity and mortality, and new therapeutic approaches are urgently needed. Recent data suggest a benefit of checkpoint inhibitors (ICI). We report the case of a diabetic patient with refractory IFD following a SARSCoV-2 infection treated by ICI and interferon-gamma associated with antifungal treatment.

Original language	English
Article number	900522
Journal	Frontiers in immunology
Volume	13
DOIs	https://doi.org/10.3389/fimmu.2022.900522
Publication status	Published - 1 Jun 2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

anti-PD 1
cerebral mucormycosis
covid-associated pulmonary aspergillosis
immunotherapy
invasive fungal disease

Access to Document

10.3389/fimmu.2022.900522

Case-report.pdfFinal published version, 1.35 MBLicence: CC BY

Cite this

Serris, A., Ouedrani, A., Uhel, F., Gazzano, M., Bedarida, V., Rouzaud, C., Bougnoux, M.-E., Raphalen, J.-H., Poirée, S., Lambotte, O., Martin-Blondel, G., & Lanternier, F. (2022). Case Report: Immune Checkpoint Blockade Plus Interferon-Γ Add-On Antifungal Therapy in the Treatment of Refractory Covid-Associated Pulmonary Aspergillosis and Cerebral Mucormycosis. Frontiers in immunology, 13, Article 900522. https://doi.org/10.3389/fimmu.2022.900522

@article{94f0081ca6864caab676db05fdc911c5,

title = "Case Report: Immune Checkpoint Blockade Plus Interferon-Γ Add-On Antifungal Therapy in the Treatment of Refractory Covid-Associated Pulmonary Aspergillosis and Cerebral Mucormycosis",

abstract = "Invasive fungal diseases (IFD) still cause substantial morbidity and mortality, and new therapeutic approaches are urgently needed. Recent data suggest a benefit of checkpoint inhibitors (ICI). We report the case of a diabetic patient with refractory IFD following a SARSCoV-2 infection treated by ICI and interferon-gamma associated with antifungal treatment.",

keywords = "anti-PD 1, cerebral mucormycosis, covid-associated pulmonary aspergillosis, immunotherapy, invasive fungal disease",

author = "Alexandra Serris and Amani Ouedrani and Fabrice Uhel and Marianne Gazzano and Vincent Bedarida and Claire Rouzaud and Marie-Elisabeth Bougnoux and Jean-Herl{\'e} Raphalen and Sylvain Poir{\'e}e and Olivier Lambotte and Guillaume Martin-Blondel and Fanny Lanternier",

note = "Publisher Copyright: Copyright {\textcopyright} 2022 Serris, Ouedrani, Uhel, Gazzano, Bedarida, Rouzaud, Bougnoux, Raphalen, Poir{\'e}e, Lambotte, Martin-Blondel and Lanternier.",

year = "2022",

month = jun,

day = "1",

doi = "10.3389/fimmu.2022.900522",

language = "English",

volume = "13",

journal = "Frontiers in immunology",

issn = "1664-3224",

publisher = "Frontiers Media SA",

}

Serris, A, Ouedrani, A, Uhel, F, Gazzano, M, Bedarida, V, Rouzaud, C, Bougnoux, M-E, Raphalen, J-H, Poirée, S, Lambotte, O, Martin-Blondel, G & Lanternier, F 2022, 'Case Report: Immune Checkpoint Blockade Plus Interferon-Γ Add-On Antifungal Therapy in the Treatment of Refractory Covid-Associated Pulmonary Aspergillosis and Cerebral Mucormycosis', Frontiers in immunology, vol. 13, 900522. https://doi.org/10.3389/fimmu.2022.900522

Case Report: Immune Checkpoint Blockade Plus Interferon-Γ Add-On Antifungal Therapy in the Treatment of Refractory Covid-Associated Pulmonary Aspergillosis and Cerebral Mucormycosis. / Serris, Alexandra; Ouedrani, Amani; Uhel, Fabrice et al.
In: Frontiers in immunology, Vol. 13, 900522, 01.06.2022.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Case Report

T2 - Immune Checkpoint Blockade Plus Interferon-Γ Add-On Antifungal Therapy in the Treatment of Refractory Covid-Associated Pulmonary Aspergillosis and Cerebral Mucormycosis

AU - Serris, Alexandra

AU - Ouedrani, Amani

AU - Uhel, Fabrice

AU - Gazzano, Marianne

AU - Bedarida, Vincent

AU - Rouzaud, Claire

AU - Bougnoux, Marie-Elisabeth

AU - Raphalen, Jean-Herlé

AU - Poirée, Sylvain

AU - Lambotte, Olivier

AU - Martin-Blondel, Guillaume

AU - Lanternier, Fanny

PY - 2022/6/1

Y1 - 2022/6/1

N2 - Invasive fungal diseases (IFD) still cause substantial morbidity and mortality, and new therapeutic approaches are urgently needed. Recent data suggest a benefit of checkpoint inhibitors (ICI). We report the case of a diabetic patient with refractory IFD following a SARSCoV-2 infection treated by ICI and interferon-gamma associated with antifungal treatment.

AB - Invasive fungal diseases (IFD) still cause substantial morbidity and mortality, and new therapeutic approaches are urgently needed. Recent data suggest a benefit of checkpoint inhibitors (ICI). We report the case of a diabetic patient with refractory IFD following a SARSCoV-2 infection treated by ICI and interferon-gamma associated with antifungal treatment.

KW - anti-PD 1

KW - cerebral mucormycosis

KW - covid-associated pulmonary aspergillosis

KW - immunotherapy

KW - invasive fungal disease

UR - https://www.scopus.com/pages/publications/85132312387

U2 - 10.3389/fimmu.2022.900522

DO - 10.3389/fimmu.2022.900522

M3 - Article

C2 - 35720319

SN - 1664-3224

VL - 13

JO - Frontiers in immunology

JF - Frontiers in immunology

M1 - 900522

ER -

Case Report: Immune Checkpoint Blockade Plus Interferon-Γ Add-On Antifungal Therapy in the Treatment of Refractory Covid-Associated Pulmonary Aspergillosis and Cerebral Mucormycosis

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this